Results 141 to 150 of about 64,427 (282)

Fluorescence in situ hybridization for the BCR–ABL fusion gene in a patient with imatinib mesylate‐resistant chronic myelogenous leukaemia in extramedullary blast crisis [PDF]

, 2003
Takehiko Mori, Rie Yamazaki, Yasuo Ikeda, Shinichiro Okamoto   +3 more
openalex   +1 more source

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Ida‐FLAG plus imatinib mesylate‐induced molecular remission in a patient with chemoresistant Ph¹(+) acute myeloid leukemia [PDF]

, 2003
Nora‐Athina Viniou, Theodoros P. Vassilakopoulos, Xanthi Giakoumi, Marina Mantzouranis, Gerassimos A. Pangalis   +4 more
openalex   +1 more source

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. [PDF]

, 2006
In chronic myeloid leukaemia, CD34(+) stem/progenitor cells appear resistant to imatinib mesylate (IM) in vitro and in vivo. To investigate the underlying mechanism(s) of IM resistance, it is essential to quantify Bcr-Abl kinase status at the stem cell ...
Copland, M, Elrick, L, Hamilton, A, Holyoake, T, Jørgensen, H, Melo, J V, Mysina, Svetlana   +6 more
core  

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. [PDF]

PLoS One, 2022
PLOS ONE Editors.
europepmc   +1 more source

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase [PDF]

, 2003
Thomas B. Sneed, Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Mary Beth Rios, B. Nebiyou Bekele, Xian Zhou, Debra Resta, William Wierda, Stefan Faderl, Francis J. Giles, Jorge E. Cortés   +11 more
openalex   +1 more source

Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status [PDF]

, 2003
Debra Resta, Martin S. Tallman, Mary Beth Riley, John L. Frater, Brian J. Druker, LoAnn Peterson, Daina Variakojis, Mary Ann Hrisinko   +7 more
openalex   +1 more source

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi

Pakistan Armed Forces Medical Journal
Objective: To find the frequency of haematological response in patients of chronic myeloid leukaemia (Chronic Phase) after three months of Imatinib Mesylate therapy, presenting to CMH Rawalpindi Study Design: Cross-sectional study.
Anil Babar, Riaz Ahmed, Ahmed Raza, Zulfiqar Ali Amin, Muhammad Nadeem Piracha, Anum Zargham, Ibtisam Idrees   +6 more
doaj   +1 more source

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. [PDF]

Front Syst Neurosci, 2022
Perkins ME, Girard BM, Campbell SE, Vizzard MA.   +3 more
europepmc   +1 more source

Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase

, 2002
Hagop M. Kantarjian, Jorge E. Cortés, Susan O’Brien, Francis J. Giles, Maher Albitar, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Debra Resta, Moshe Talpaz   +11 more
openalex   +1 more source